comparemela.com

Latest Breaking News On - Adverse events pharmacology - Page 2 : comparemela.com

Angioedema Risk Jumps When Switching HF Meds

The risk for angioedema increases when switching from an ARB or ACE inhibitor to ARNI, observational data suggest. Better to start RAS inhibition using the ARNI in the first place, researchers say.

American college of cardiologyUnited statesSilver springEfe eworukeUniversity of colorado skaggs school pharmacySciences in auroraJournal of the american college cardiologyDrug administrationHarvard medical schoolAmerican collegeRare complicationDrug evaluationColorado skaggs schoolPharmaceutical sciencesHeart failureAcquired angioedema

LAMA/LABA Combos Tied to Varying Adverse Events in COPD

A national cohort study showed significant differences in AE and cardiovascular event risk among three treatments.

Ching fu wengNational death registryNational health insurance research databaseHsinchu cathay general hospitalChronic obstructive pulmonary disease copdChronic obstructive pulmonary diseaseChronic obstructive lung diseaseAdverse events pharmacologyAdverse effectsSide effectsAcute myocardial infarctionHealth insuranceDherence to medication issues for patientsBeta adrenergic blockers

Follow-up Trial of Myeloma Drug Flopped, Says FDA Panel

Oncopeptides failed to persuade FDA advisers that a post hoc analysis shows a benefit to its myeloma drug, melphalan flufenamide, which received accelerated approval in early 2021.

United statesDavid mitchellMikkaela sekeresJakob lindbergOncologic drugs advisory committeeUniversity of coloradoUniversity of miamiEuropean medicines agencyEuropean commissionDrug administrationDrugs advisory committeeMultiple myelomaPlasma cell myelomaUs food and drug administrationNited states food and drug administrationAlignant neoplasia

FDA OKs Sodium Thiosulfate for Ototoxicity Risk in Peds Cancer

This makes sodium thiosulfate the first and only FDA-approved treatment for this indication and patient population.

United statesLos angelesDavidr freyerFennec pharmaceuticalsDrug administrationHospital los angelesNt earsHearing impairmentHearing lossAdverse events pharmacologyUs food and drug administrationNited states food and drug administrationAdverse effectsSide effectsAlignant neoplasia

Brodalumab Suicide Risk Similar to Other Biologics, Study Finds

Researchers evaluated data on the number of completed suicides for brodalumab and 10 other biologics approved for psoriasis from the FDA s Adverse Events Reporting System through the end of 2021.

United statesSan franciscoGeorge hanJohn kooSamuel yeroushalmiSkin treatment centerUniversity of californiaGeorge washington universityDrug administrationZucker school of medicine at hofstra northwellJournal of the american academy dermatologyRisk evaluationMitigation strategiesEvents reporting systemAmerican academyZucker school

vimarsana © 2020. All Rights Reserved.